AVN944 297730-17-7 AVN-944(VX-944) is a selective, noncompetitive inhibitor of the enzyme directed against human IMPDH with Ki of 6-10 nM for IMPDH1/IMPDH2.

YL-109 36341-25-0 YL-109 is a novel anticancer agent which has ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo.

L-779450 303727-31-3 L-779450 is a potent, ATP-competitive Raf kinase inhibitor (IC50 =10 nM) that displays 7, 30 and 70-fold selectivity over p38α, GSK3β and Lck respectively.

Asenapine Maleate 85650-56-2 Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered

FLT3-IN-2 923562-23-6 FLT3-IN-2 is a FLT3 inhibitor with IC50 of ＜ 1 μM, detailed information refer to WO 2012158957 A2 and WO 2007013896.

NVP 231 362003-83-6 NVP-231 is a potent, specific, and reversible CerK inhibitor(IC50=12±2 nM) that competitively inhibits binding of ceramide to CerK.

MK3697 1224846-01-8 MK-3697 is an isonicotinamide small molecule, acting as a potent and selective Orexin 2 receptor antagonist with Ki = 0.95 nM.

GSK2110183 1047644-62-1 GSK2110183 is a potent pan-AKT inhibitor that demonstrated synergy with bortezomib in preclinical models of multiple myeloma (MM).